Good day, and thank you for standing by. Welcome to the Q3 2021 West Pharmaceutical Services earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star and then the number one on your telephone. Please be advised that today's conference call is being recorded. If you require assistance during the conference, press star and then the number zero. I would now like to hand the conference over to Quintin Lai, Vice President of Investor Relations. Please go ahead. Thank you, Amanda. Good morning, and welcome to West third quarter 2021 conference call. We issued our financial results this morning, and the release has been posted in the investors section on the company's website, located at westpharma.com. This morning, CEO Eric Green and CFO Bernard Birkett will review our financial results, provide an update on our business, and present an update on our full year 2021 financial guidance. There's a slide presentation that accompanies today's call, and a copy of the presentation is available on the investor section of our website. On slide four is our safe harbor statement. Statements made by the management on this call and in the accompanying presentation contain forward-looking statements within the meaning of U.S. Federal Securities Law. These statements are based on our beliefs and assumptions, current expectations, estimates, and forecasts. The company's future results are influenced by many factors beyond the control of the company. Actual results could differ materially from past results as well as those expressed or implied in any forward-looking statement made here. Please refer to today's press release as well as any other disclosures made by the company regarding the risks to which it is subject, including our 10-K, 10-Q, and 8-K reports. During today's call, management will make reference to non-GAAP financial measures, including organic sales growth, adjusted operating profit, adjusted operating profit margin, and adjusted diluted EPS. Reconciliations and limitations of the non-GAAP financial measures to the most comparable financial results prepared in conformity to GAAP are provided in this morning's earnings release. I now turn the call over to West CEO and President, Eric Green. Thank you, Quintin, and good morning, everyone, and thanks for joining us today. We will start on slide five. Our team delivered an incredibly strong third quarter. Our proven market-led strategy delivered double-digit growth across all three market units and geographies. Excluding positive impact from sales related to the pandemic, we delivered double-digit growth in our base business. With continued strong adoption of our high-value products, coupled with solid execution and leveraging our global operating model, it has led to robust margin expansion and EPS growth for the quarter. Our Q3 performance was made possible by the commitment of the West team members across the globe. We are in the business of helping our customers bring new medicines and treatments that improve the lives of patients. I'm very proud and humbled of how we live our purpose by producing billions of components and devices each quarter. We do so with the knowledge that each and every component we make is impacting patients' life. We continue to fulfill our purpose by earning our customers' trust by leading with quality, service, and science. Looking ahead, we are well-positioned with the right growth strategy. Our committed order book remains robust. We continue to capture the benefits of the globalization of our operating network and continued capital investments to support the increasing demand driven by the pandemic and attractive end markets. With this substantial momentum, we are raising our sales and EPS guidance for the full year 2021, and for the 29th consecutive year, we are increasing the company's dividend. Bernard will go into greater detail shortly. Turning to slide six. Our key drivers of growth in Q3 are being fueled by COVID-19 customers that are using our stoppers and seals, including the highest level of NovaPure and FluroTec. Biologic customers that are shifting preference from FluroTec to our premium platform, NovaPure, to achieve the highest quality and tightest specifications for their newly approved biologic drugs. Pharma and generic customers that are increasing orders as their demand grows for non-COVID-19 vaccines and injectable drugs. Shifting to our device portfolio and our long-standing partnership with Daiichi Sankyo, we continue to see adoption and uptick of customer interest for new pipeline drugs with Crystal Zenith syringes, cartridges, and vials. To meet this demand and stay ahead of the current growth trends for future approvals, we have continued to add manufacturing capacity for CZ. Our teams have successfully validated additional lines for insert needle syringes and will begin producing commercial product by the end of the year. All these products, as well as other HVP components, are contributing to our growing book of committed orders, which position us well for the remainder of the year and into 2022 and beyond. Moving to slide seven. To date, we have been leveraging our global infrastructure and tapping it into the agility of our own team to meet the increased customer orders. As we highlighted in Q2, several phases of investment are proceeding and now being realized. Since the onset of the pandemic, we have expanded capacity at 13 existing sites with 30 major facility modifications, dedicated over $300 million of capital, and added over 400 incremental pieces of equipment, all while keeping pace with the growing base demand and moving our operations to 24/7. As our book of committed orders continues to surge, we will continue to make further strategic investments to meet demand. Today, we're announcing a fourth phase of capacity expansion that will commence in 2022. This will primarily focus on expanding NovaPure production at our HVP sites in the United States and Europe. Shifting to the rapidly changing environment and the impact of COVID-19 on the global supply chain, no industry has been immune to this impact. We're working with our partners to help overcome challenges that span from transportation to logistics to raw materials and securing labor, all leading to cost inflation and delays. We are successfully navigating this environment, thanks in part to our unsurpassed manufacturing footprint that will continue to serve our business well as we operate through these unprecedented times. Turning to slide eight. I'm proud of the significant progress we have made on our ESG priorities. These have been an integral part of our One West culture and our commitment to all our stakeholders and the communities where we work and live. Over the past six years, we continue to raise the bar in all aspects of our ESG initiatives, and we remain on track to publish by year-end a supplement to our 2020 Corporate Responsibility Report incorporating the SASB and TCFD ESG standards. Now I'll turn it over to our CFO, Bernard Birkett, who will provide more detail on the financial performance. Bernard? Thank you, Eric, and good morning. Let's review the numbers in more detail. We'll first look at Q3 2021 revenues and profits, where we saw continued strong sales and EPS growth, led by strong revenue performance in our biologics, generics, and pharma market units. I will take you through the margin growth we saw in the quarter, as well as some balance sheet takeaways. Finally, we will provide an update to our 2021 guidance. First up, Q3. Our financial results are summarized on slide nine, and the reconciliation of non-GAAP measures are described in slides 17-21. We recorded net sales of $706.5 million, representing organic sales growth of 27.9%. COVID-related net revenues are estimated to have been approximately $115 million in the quarter. These net revenues include our assessment of components associated with vaccines, treatment, and diagnosis of COVID-19 patients, offset by lower sales to customers affected by lower volumes due to the pandemic. Looking at slide 10, proprietary product sales grew organically by 35.7% in the quarter. High-value products, which made up approximately 73% of proprietary product sales in the quarter, grew double digits and had solid momentum across all of our market units in Q3. Looking at the performance of the market units, the biologics market unit delivered strong double-digit growth. We continue to work with many of both biotech and biopharma customers who are using West and Daikyo high-value product offerings. The generics market unit also experienced double-digit growth, led by sales of FluroTec and Westar components. Our pharma market units also saw a strong double-digit growth with sales led by high-value products including Westar, FluroTec, and NovaPure components. Contract manufacturing had low single-digit organic sales growth for the third quarter, led once again by sales of healthcare-related medical devices. We continue to see improvement in gross profit. We recorded $288.2 million in gross profit, $93.6 million or 48.1% above Q3 of last year. Our gross profit margin of 14.8% was a 530 basis point expansion from the same period last year. We saw improvement in adjusted operating profit with $182.8 million recorded this quarter, compared to $103.9 million in the same period last year, for a 75.9% increase. Our adjusted operating profit margin, 25.9%, was a 690 basis point increase from the same period last year. Finally, adjusted diluted EPS grew 79% for Q3. Excluding stock-based compensation tax benefit of $0.11 in Q3, EPS grew by approximately 72%. Let's review the growth drivers in both revenue and profit. On slide 11, we show the contributions to sales growth in the quarter. Volume and mix contributed $142.9 million, or 26.1 percentage points of growth, including approximately $83 million of incremental volume driven by COVID-19 related net demand. Sales price increases contributed $10.1 million or 1.8 percentage points of growth. Looking at margin performance, slide 19 shows our consolidated gross profit margin 40.8% for Q3 2021, up from 35.5% in Q3 2020. Proprietary Products third quarter gross profit margin of 46.3% was 550 basis points above the margin achieved in the third quarter of 2020. The key drivers for continued improvements in Proprietary Products gross profit margin were favorable mix of products sold, driven by high-growth in high-value products, production efficiencies, and sales price increases, partially offset by increased overhead costs inclusive of compensation. Contract Manufacturing third quarter gross profit margin of 16.1% was 180 basis points below the margin achieved in the quarter of 2020. The decrease in margin is largely attributed to mix of products sold, as well as timing of the pass-through of raw material price increases to customers. Now let's look at our balance sheet takeaway and review how we've done in terms of generating more cash for the business. On slide 13, we have listed some key cash flow metrics. Operating cash flow was $423.2 million for the third quarter of 2021, an increase of $99.4 million compared to the same period last year, a 30.7% increase. Operating cash flow in the period was adversely impacted by a working capital increase as well as timing of tax payment. Our third quarter 2021 year-to-date capital spending was $176.9 million, $60.2 million higher than the same period last year. Working capital of approximately $1 billion at September 30, 2021, increased by $169.4 million from December 31, 2020, primarily due to higher accounts receivable from our increased sales. Our cash balance at September 30 of $688 million was $72.5 million higher than our December 2020 balance. The increase in cash is primarily due to our strong operating results in the period, offset by our share repurchase program and higher CapEx. Turning to guidance, slide four provides a high-level summary. Full year 2021 net sales are expected to be in a range of $2.8 billion-$2.81 billion compared to a prior guidance range of $2.76 billion-$2.785 billion. This guidance includes estimated net COVID incremental revenues of approximately $450 million. There is an estimated benefit of $55 million based on current foreign exchange rates compared to a prior estimated benefit of $80 million. This $25 million reduction in FX tailwind has been absorbed into our guidance. We expect organic sales growth to be approximately 28% compared to a prior range of 24%-25%. We expect our full year 2021 reported diluted EPS guidance to be in a range of $8.40-$8.50 compared to a prior range of $8.05-$8.20. This revised guidance includes a $0.35 EPS positive impact of tax benefits from stock-based compensation from the first nine months of 2021. Also, our CapEx guidance remains at $265 million-$275 million for the year. There are some key elements I want to bring your attention to as we review our guidance. Estimated FX benefit on EPS has an impact of approximately $0.19 based on current foreign currency exchange rates compared to a prior estimated benefit of $0.27. Our guidance excludes future tax benefits from stock-based compensation. To summarize the key takeaways for the third quarter, strong top line growth in Proprietary, gross profit margin improvement, growth in operating profit margin, growth in adjusted diluted EPS, and growth in operating cash flow, delivering in line with our pillars of execute, innovate, and grow. I'd now like to turn the call back over to Eric. Great. Thank you, Bernard. To summarize on slide 15, the excellent financial performance reported today continues to reaffirm that our strategy is working. Our market-led approach is delivering unique value to our customers. Our global operations team is efficiently manufacturing and delivering product in this complex environment with a focus on service and quality. We're continuing to accelerate capital spending across our operations to meet current and anticipated future growth. Most importantly, we have an incredible team working to make this all happen. We are proud to serve as a valuable, trusted partner for customers to support patient health and look forward to continuing to play a critical role in delivering healthcare well into the future. Amanda, we're ready to take questions. Thank you. Thank you. As a reminder, to ask a question, you will need to press star and then the number one on your telephone. To withdraw your question, please press the pound key. Our first question comes to the line of Larry Solow from CJS Securities. Your line is now open. Thank you very much. Congratulations on another good quarter. Sounds like the outlook, Eric, continues to improve. Maybe you can just discuss a little bit on the additional capacity expansions today that you announced on NovaPure. It sounds like just another acceleration from planned capacity expansion that was probably a couple years originally gonna be a couple years out. Maybe is this NovaPure your expansion driven more on the base business. On the vaccine side, is that more of a mix? Maybe you can give us a little color on that. Larry, thanks for the question and good morning. No, you're absolutely correct. What we're seeing with the additional capital expansion is it was planned for further years out, brought it forward. This is more of a demand of both areas of biologics, new drug molecules being launched and around the NovaPure, particularly around the plungers, and also the life cycle management of COVID vaccines as you think about various configurations, whether it's in a vial configuration or a prefilled syringe. It is a mixed effect, and we brought it forward based on our discussions with customers and commitments that obviously we're making for them but also what they're making towards us. In terms of the life cycle management on the COVID vaccines, do you see this, you know, proliferating more into, you know, as it goes more into the doctor's offices and maybe less on the mass vaccine basis where it's at community centers and whatnot? I would imagine that benefits you. Do you have any visibility on that you can share with us in terms of dosing, switching maybe from, you know, five, 10 per vial to down to single doses? Well, Larry, those conversations are ongoing right now. It's when we look at the current mix that we have for our customers, it's still mostly in regards to the COVID-19 vaccines. It's still mostly within vials and multiple doses for vials. We continue to prepare ourselves as things do change over time. The near term, near future, we're really focused on meeting the current configuration. Think about our capital expansions. They're taking typically between one, let's call it 12-18 months to get in, validated and start scaling up production. That's the type of timeline we're looking at as far as preparing ourselves for any additional demand and other configurations. Gotcha. Just last, a quick one. I saw you guys had put a release on this, and this might just be a small little additional service offering to you guys on this modeling platform that you put out. I think that was presented at an industry meeting a couple weeks ago. Is there any color on that, this sort of online, I guess it helps customers design their packaging needs and whatnot. Any color on that? Yeah, Larry, one of the drivers, if you think about our pillars of strategy under execute, one of the key drivers of being market led is digitization, obviously internally but externally for our customers and also digitization of product. Now, same focus on customers. What we have, a wealth of data and science information that we've developed in our laboratories and working with the customers over the years. What we've been able to do is fuse together our digital capabilities that we've been building over the last couple years with a predictive modeling capability, which is a more data-driven offering. As you can imagine, a customer trying to identify with their complex molecule that they're looking at developing and obviously ultimately commercializing, what is the ideal packaging configuration? That is where we're bringing that data to the forefront, leading with science, being that scientific destination choice for our customers and providing that, those insights. More to come. We're excited that we launched this, but I am- Mm-hmm. For me personally, it's a great example of our leadership position in leading with science for our customers. Absolutely. Look forward to learning more about that. Okay, great, Eric. Thanks, Eric. I appreciate the thoughts. Thanks, Larry. Thank you. Our next question comes from John Kreger from William Blair. Your line is now open. A question about COVID visibility. Based upon your discussions with clients and your order book, when would you expect your COVID volumes to start to tail off? Well, right now, the way we see our confirmed order book on a complete, if you look at it as a complete order book, committed book, you'll find that the COVID piece continues to increase. It's not the majority of it, but it is continuously increased, and we have good visibility going into 2022. John, a lot of the investments that we've made, committed to last year and the one we just spoke of today, a good portion of that is related to COVID vaccines to support not just the demands in the more mature markets, but basically on a global basis. I won't give a number out on the COVID piece, but it's still very robust for us. Okay, thanks. The COVID 2022 outlook would appear to be up from 2021? Well, there's a lot of factors, John, in that, but right now, the way we're discussing here with customers expanding capacity and building the capabilities in our plants, we anticipate similar, if not a little more, stronger, demand in 2022. Sounds good. We're also seeing it's not just the COVID demand that the CapEx expansions are for. It's for our core business demand. As Eric alluded to earlier, it's like we are seeing strong growth in those areas as well, so that the CapEx is not just reliant on COVID. It's there to support our business over the short, medium, and long term. You know, we have enough capacity over time or enough demand to fill that capacity when it starts to come online. That's good. Thanks, Bernard. Actually, a follow-up question for you on margins. Given the surge that you guys have seen over the last year, what is your comfort level that they can be sustained as you think about longer term planning? Or should we think about those margins to kind of come back to the older trend line once COVID volumes start to normalize? I wouldn't see the margins coming back to where they were. I think the gains that we have, you know, gained over the last 12-24 months. Our plan is to hold on to those and actually expand margins further as we move out over the next number of years. You can see it in the dynamic of our business and where the growth is actually coming from. It's a lot of it is placed within the biologics market unit, and that is driving a lot of the growth on revenue, but plus on margins. Again, it's not specifically reliant on COVID. It's within our core business. What we're actually seeing, and you can see on some of the call-outs, the growth that we're seeing around generics and pharma, you know, we are seeing the high-value products getting traction in those areas also. Coupled with the efficiencies that we're forecasting to come from operations, we believe that we will continue to expand margins. Will it be at the same pace as what we're experiencing here in 2021? That's something that we, you know, give further information on when we guide here in the first part of 2022. All right, sounds good. Thank you. Our next question comes to the line of Derik De Bruin from Bank of America. Your line is now open. Hey, good morning. Morning, Derik. Hi. A couple of questions. I think first one, can you talk a little about the contract manufacturing segment, a little bit lower than what we had forecast, and also, comps start getting easier next quarter. Should we start to think about starting next quarter, you're back at sort of that high single digit, low double-digit growth rates that your long-term guide implies? Yeah. If you're talking about getting to the end of 2021, I wouldn't see- Yeah. Yeah. I wouldn't see any acceleration in the growth rate in that time frame. My expectation is it'll be pretty similar to what we saw here in Q3. We have been signaling that, you know, talking about that for a long time, that the growth in contract manufacturing would modify for a period of time. As we move into 2022 and 2023, we would expect to see that growth begin to accelerate again, but more in line with kind of mid-single digit growth rates rather than the like double-digit growth rates that we had experienced in 17 and 18. We've looked at the mix of our business and looked at you know where we should be deploying our capital to make sure that we are getting growth rates but also that it's on our proprietary side. We're still very focused on contract but I wouldn't see it growing at double digits. Great. That's really helpful color. Can we talk a little bit about how you're sort of thinking about CapEx over the next 2022, 2023 time period? I mean, since you're pointing some things forward, should we expect similar levels next year? That's one. I guess, what's the revenue potential for the additional capacity expansions that you've got ongoing overall? As Eric said, we're seeing very, very strong demand both within our core business and responding to COVID. You know, our CapEx stepped up in 2020 and here again in 2021. We're not gonna guide to a number for 2022, but it will be a little bit higher than what we would have normally, you know, guided to the streets on that 6-7. What we're seeing is, if you look at it over the last probably, you know, 12 to 18 months, we're stepping up capital on an incremental basis, understanding that the demand is there so that we can feed into it pretty quickly. All of the capital expansions are tied into demands that we can see, you know, coming from customers over the 2022-2023 time horizon. Great. Can you talk a little bit more about being able to pass on pricing, raw materials? Just we're getting a lot of questions from clients on those topics across the board, but we'd love to hear you sort of elaborate more on the supply chain and pricing dynamics. We've been passing on, you know, cost increases to customers again throughout 2020 and 2021, particularly on freight. You know, as freight charges and logistical charges increased, we were able to pass those on to many of our customers. On components, on specific components where we have seen price increases, both within contract manufacturing and in our proprietary business, we have been passing those on to our customers and obviously keeping them in the loop as to what's happening, but you know what are driving these price increases that we're passing on. Also as we look out into 2022, we have various mechanisms in place to enable us to pass on, you know, many of these increases. It depends on, you know, what the relationship with the customer, whether it's contracted business or not. In the various sectors, we have various tools that we employ. We're able to, you know, we don't have to absorb the majority of those inflationary costs. Then also we're working on the other side to make sure that we're getting leaner and more efficient and, you know, to make sure that we can, you know, deal with those from that angle as well. There's a multifaceted approach. Great. Thank you. Our next question comes from the line of Paul Knight with KeyBanc. Your line is open. When you plan this CapEx and look at future demand, is it emanating from fill and finish customers, or is it emanating from the therapeutic programs that are in, like, stability trials? How do you pinpoint what this demand may look like in even 2023 and outer? Yeah, Paul, the driver of the demand expansion or the demand increase that we're seeing and requiring capacity expansion is really driven by the therapeutic companies, strictly with the drug customers, not the fill finish. As you know, it's a whole ecosystem, and we know where we play, but our interactions are directly with the drug customers. What's also exciting is to see that it's not just concentrated in one area, i.e. biologics. It's also we're starting to see pickup in small molecules also, which is good for our long-term franchise. Yeah, absolutely, the drug customers. As you look at your capacity expansion, are you having to, is it 12-18 months with customer validation? Are you running into challenges that I'm guessing some of these are even greenfield sites, so will you have to stretch out that? What is the duration of a build to actually produce revenue timeline? Yeah, Paul, you know, what's fascinating about what's actually quite exciting is that a few years ago, we made the strategic decision to start creating centers of excellence and started to consolidate our manufacturing into particular sites throughout the world and became more effective through lean systems, working with our customers through our quality systems, also in processes to create more of an operating network. The short answer to your question is this is not greenfield. A lot of the investments we're making right now are physical equipment, process expansions, maybe a modular approach in some sites. You've been to Waterford. We'll be looking at maybe expanding that site with another modular addition on the side, but it's leveraging existing facilities. When you add it all up, it really comes down to how fast we can have the equipment manufactured, delivered, installed, and gone through validation. Since a lot of the equipment is replicating what's in place already, the validation process with customers is very short. We could have some expansion up and running in less than just a couple quarters. Some other expansions might take, you know, four or five quarters to get up and running. Yeah, Paul, as soon as the Okay, thanks. As soon as the equipment hits the production floor and is validated, it's operational. We have demand to feed into it straight away. The payback on the capital is pretty quick for us at this point. Again, that's why we're doing this phased approach, so we can manage this appropriately. Okay. Thank you. Thanks, Paul. Our next question comes from the line of Dave Windley from Jefferies. Your line is now open. Morning. I wanted to ask a few. First one is whether or not your views on your COVID revenue for the full year change with the results that you posted in the third quarter. Is it still $430 million? No, it's 4, 450. 450. Okay. Yeah, we called out. Okay. Sorry, I missed that. On innovation, Eric, the CZ was a topic of conversation really dating back to before your tenure, got quiet for a while, and I hear you calling it out again. I guess I'm interested in, you know, maybe some color around the drivers of that. Has the company kind of enhanced the material or worked through some you know developmental bottlenecks with clients that's allowed that to kind of break free on a renewed basis? Yeah, Dave. If you think about the device portfolio, let's just call it roughly 5% or less on the proprietary side, so 5% of the business. CZ is the largest portion of that. What we're seeing is the reality is we're continuously optimizing the product and coming out with new line extensions. However, it's taken a while to seed the market and gain confidence and traction. Once it starts becoming quite common use for the high-end biologics, we're seeing that acceleration. In particular with the insert needle syringes that we have been producing in Arizona, we're actually at the stage of doubling capacity by the end of this year, and that's what was referenced. When you think about the growth, which is above the company average, significantly above the company average, we do see through the number of approvals of drugs in the market, plus what's in the pipeline that's being reviewed as we speak, that this is an exciting area. It has taken time. You're right, Dave. This has been discussed for a number of years, but now it's becoming more noticeable in our growth numbers, particularly around devices. Sticking with innovation, in previous commentary, you've talked about, hey, NovaPure is not the end of the road. We're not done with NovaPure. We wanna continue to innovate. Any comments on that front? Is NovaPure Prime in the offing at any time in the near future? Well, I don't know if I can use that now because I'll have to notify you. But I will say, stay tuned. I gotta be careful in that category. But I will tell you this, what's really exciting is that the teams that we've put together, particularly with the market-led approach, we're getting better insights on where we are headed, on what products are being pulled by our customers and what problems we're trying to solve. You know, I know earlier we just briefly mentioned a new digital tool, and that actually was Deltacube. That was actually derived from conversations with our customers. Wouldn't it be great if we could do this? Stay tuned on that question. We're constantly developing and, but be assured though, they will be products that are being pulled by our customers today. Got it. Last question for me is around capital deployment. You've talked at times about being interested in acquisitions. I can imagine that maybe finding what you wanted at attractive prices might be a little hard in this market. Raised the dividend, but not by much. Is there any appetite given the growing cash on the balance sheet to say, you know, make the dividend more substantial, or are you holding it back for acquisitions? What's your thought around cash? Well, I would say the first priority, Dave, and particularly in the environment that we're in today, is to continue to fuel the very robust organic growth that we have in our hands and that we're dealing with. It's a great problem to solve, right? We're gonna continue to invest in our own infrastructure. What I'm excited about is that it's a really short payback, and it's expanding current portfolio. We do think there's opportunities on the M&A front, and we're continuously building that capability out here. Our primary focus, I'll tell you, is laser focused on execution. We're opening up our discussions broader than that today. Thank you. Thanks, Dave. I'm showing no further questions at this time. I would like to turn the call back over to Quintin Lai for closing remarks. Thanks, Amanda, and thank you for joining us on today's conference call. An online archive of the broadcast will be available on our website at westpharma.com in the investor section. Additionally, you can access a replay through Thursday, November 4 by using the dial-in numbers and conference ID provided at the end of today's earnings release. This concludes today's call. Have a nice day. Thank you. This does conclude today's conference call. Thank you for participating. You may now disconnect.